Aixin Life International, Inc. reported that, effective May 18, 2026, board member Mr. Xinliang Li, also known as Christopher Lee, resigned from the Board of Directors. He previously served on the Compensation Committee, Nominating and Corporate Governance Committee, and was Chair of the Audit Committee.
The company states that Mr. Lee’s resignation was not due to any disagreement with the company regarding its operations, policies, or practices, including financial matters. The filing also includes standard cautionary language about forward-looking statements related to planned acquisitions and future performance.
AiXin Life International, Inc. notified the SEC that it cannot timely file its Quarterly Report on Form 10-Q for the period ended March 31, 2026 because the company has not completed the required financial statements and review procedures. The filing states the delay "could not be eliminated without unreasonable effort or expense" and that preliminary results for the quarter are not yet available. The notification was signed by Quanzhong Lin on May 16, 2026.
AiXin Life International, Inc. files its annual report describing a China-based health and wellness business that develops, manufactures and sells nutritional supplements through pharmacies, direct marketing, wholesale and online channels. The company reports continued net losses, cash burn and a working capital deficit that raise substantial doubt about its ability to continue as a going concern.
AiXin highlights expansion moves, including a production facility in Yunnan and a leased hotel property in Chengdu to support marketing events and wellness activities, but remains highly exposed to intense competition, complex PRC regulations, geopolitical tensions and potential U.S. listing risks tied to evolving rules such as the Holding Foreign Companies Accountable Act.
AiXin Life International requested withdrawal of its Form S-1 registration statement (File No. 333-268190), stating it will not proceed with the offering.
The company states No securities have been issued or sold under the Registration Statement and that the Registration Statement has not been declared effective. The letter cites Rule 477 and notes the application will be deemed granted as filed unless the Commission objects within fifteen days.
Aixin Life International, Inc. reported a leadership change, appointing Qiyu Jiang, age 40, as a director and as Secretary of the company and its subsidiaries effective April 15, 2026. Jiang has experience in investment management, legal work for private funds, and independent options trading, and holds business and legal qualifications.
AiXin Life International, Inc. notified the SEC that it will not timely file its Annual Report on Form 10-K for the period ended December 31, 2025 due to a delay in completing the required financial statements and related review procedures that the company says could not be eliminated without unreasonable effort or expense. The notification was signed by CEO Quanzhong Lin on April 1, 2026.
AiXin Life International, Inc. reported that its Board of Directors accepted the resignation of director Yao-te Wang, effective January 26, 2026. At the same time, Mr. Wang was removed from all officer roles he held at the company and its subsidiaries. The filing does not describe any replacement or other changes, focusing solely on his departure from the board and executive positions.
Aixin Life International (AIXN) reported another weak quarter for the three months ended September 30, 2025. Net revenue fell to $301,979 from $936,406 a year earlier, as direct sales and pharmacy revenue declined sharply, while hotel and manufacturing segments also generated lower sales. The company posted a quarterly net loss of $340,461, though this was narrower than the prior-year loss of $546,186.
For the first nine months of 2025, revenue dropped to $1.16 million from $3.12 million, and the net loss widened slightly to $1.41 million. Operating cash outflow increased to $1.77 million, partly funded by $3.28 million of advances from related parties, leaving cash at only $19,113 and a working capital deficit of $6.77 million. Total liabilities of $9.20 million, including $5.46 million due to related parties, exceed total assets of $3.37 million, resulting in a stockholders’ deficit of $5.82 million. Management discloses that these conditions raise substantial doubt about the company’s ability to continue as a going concern and plans to rely on cost controls, higher-margin products, related-party loans, and potential equity offerings.
AiXin Life International, Inc. filed a notice of late Form 10-Q for the quarter ended September 30, 2025, citing delays in completing its financial statements and related review procedures that it says could not be resolved without unreasonable effort or expense. The company expects to use the five-day extension period allowed under SEC rules.
Based on preliminary results, AiXin anticipates revenue of about $301,979 for the third quarter and $1,161,739 for the first nine months of 2025, down from $936,406 and $3,120,615 in the same 2024 periods. It expects a comprehensive loss of roughly $374,458 for the third quarter of 2025 versus a loss of $642,319 a year earlier, and a nine-month comprehensive loss of about $1,541,996 compared with $1,369,754 in 2024. The company states there is substantial doubt about its ability to continue as a going concern, and these preliminary figures do not reflect any potential adjustments that could result if it is unable to continue operating.